Sage Therapeutics share price today

(SAGE)

Sage Therapeutics share price is $5.61 & ₹476.72 as on 21 Dec 2024, 2.30 'hrs' IST

$5.61

▲

0.61

(12.2%)

Market is closed - opens 8 PM, 23 Dec 2024

View live Sage Therapeutics share price in Dollar and Rupees. Guide to invest in Sage Therapeutics from India. Also see the sentimental analysis on Indian investors investing in Sage Therapeutics. Get details on the Indian mutual funds that are investing in Sage Therapeutics. Get Analyst recommendations and forecasts along with all the Sage Therapeutics's financials.

Sage Therapeutics share price movements

Today's Low: $4.96
Today's High: $5.61
$5.61
11.59%
Downside
Day's Volatility :11.59%
Upside
0.0%
52 Weeks Low: $4.62
52 Weeks High: $28.26
$5.61
17.65%
Downside
52 Weeks Volatility :83.65%
Upside
80.15%

Sage Therapeutics Returns

Period	Sage Therapeutics Inc	Sector (Health Care)	Index (Russel 2000)
3 Months	-22.41%	-11.1%	0.0%
6 Months	-51.47%	-6.0%	0.0%
1 Year	-74.32%	2.7%	0.0%
3 Years	-86.65%	0.6%	-19.7%

Sage Therapeutics Key Statistics

in dollars & INR

Previous Close	$5.0
Open	$5.06
Today's High	$5.61
Today's Low	$4.96
Market Capitalization	$305.9M
Today's Volume	$4.3M
52 Week High	$28.26
52 Week Low	$4.62
Revenue TTM	$106.4M
EBITDA	$-371.2M
Earnings Per Share (EPS)	$-5.57
Profit Margin	0.0%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-49.34%

How to invest in Sage Therapeutics from India?

It is very easy for Indian residents to invest directly in Sage Therapeutics from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Sage Therapeutics stock in both Indian Rupees (INR) and US Dollars (USD). Search for Sage Therapeutics or SAGE on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Sage Therapeutics or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Sage Therapeutics shares which would translate to 0.151 fractional shares of Sage Therapeutics as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India , including recognised companies like Sage Therapeutics, in just a few clicks!

Returns in Sage Therapeutics for Indian investors in Rupees

Investment Value

₹1,00,000

Sage Therapeutics investment value today

Current value as on today

₹1,76,521

Returns

₹76,521

(+76.52%)

Returns from Sage Therapeutics Stock

₹74,325 (false-74.32%)

Dollar Returns

₹2,196 (+2.2%)

Indian investors sentiment towards Sage Therapeutics

Period: Sep 21, 2024 to Dec 20, 2024. Change in 30 Days versus previous period

Search volume for Sage Therapeutics on INDmoney from India has grown in the last 30 days as on Dec 21, 2024. 0% more investors are searching Sage Therapeutics in the last 30 days versus the previous period.

Global Institutional Holdings in Sage Therapeutics

Vanguard Group Inc
9.42%
RTW INVESTMENTS, LLC
9.14%
FMR Inc
8.62%
BlackRock Inc
8.53%
Bellevue Group AG
7.29%
State Street Corp
4.78%

Analyst Recommendation on Sage Therapeutics

Hold

33%Buy

62%Hold

3%Sell

Based on 27 Wall street analysts offering stock ratings for Sage Therapeutics(by analysts ranked 0 to 5 stars)

Based on 27 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Sage Therapeutics

What analysts predicted

Upside of 60.43%

Current:

$5.61

Target:

$9.00

Insights on Sage Therapeutics

Price Movement
In the last 7 days, SAGE stock has moved up by 4.2%
Increasing Revenue
Revenue is up for the last 3 quarters, 7.90M → 11.87M (in $), with an average increase of 17.9% per quarter
Increasing Net Profit
Netprofit is up for the last 3 quarters, -108.48M → -93.55M (in $), with an average increase of 7.7% per quarter
SAGE vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 35.5% return, outperforming this stock by 109.4%
SAGE vs VRTX (3 yr)
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 23.0% return, outperforming this stock by 109.4%
Price to Sales
ForSAGE every $1 of sales, investors are willing to pay $3.2, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $14.9 for every $1 of sales.

Sage Therapeutics Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	$90.3M	-
Net Income	$-372.9M	↑ 38.04%
Net Profit Margin	-413.06%	-

	FY19	Y/Y Change
Revenue	$6.9M	↓ 92.39%
Net Income	$-650.2M	↑ 74.36%
Net Profit Margin	-9.5K%	↓ 9053.32%

	FY20	Y/Y Change
Revenue	$1.1B	↑ 16123.06%
Net Income	$606.1M	↓ 193.22%
Net Profit Margin	54.4%	↑ 9520.78%

	FY21	Y/Y Change
Revenue	$6.3M	↓ 99.43%
Net Income	$-450.8M	↓ 174.38%
Net Profit Margin	-7.1K%	↓ 7201.31%

	FY22	Y/Y Change
Revenue	$7.7M	↑ 21.85%
Net Income	$-503.3M	↑ 11.63%
Net Profit Margin	-6.5K%	↑ 599.07%

	FY23	Y/Y Change
Revenue	$86.5M	↑ 1024.84%
Net Income	$-541.5M	↑ 7.59%
Net Profit Margin	-626.32%	↑ 5921.52%

	Q2 FY23	Q/Q Change
Revenue	$2.5M	↓ 24.89%
Net Income	$-160.3M	↑ 16.02%
Net Profit Margin	-6.5K%	↓ 2285.32%

	Q3 FY23	Q/Q Change
Revenue	$2.7M	↑ 9.78%
Net Income	$-201.6M	↑ 25.76%
Net Profit Margin	-7.4K%	↓ 943.38%

	Q4 FY23	Q/Q Change
Revenue	$78.0M	↑ 2770.84%
Net Income	$-32.7M	↓ 83.78%
Net Profit Margin	-41.95%	↑ 7381.83%

	Q1 FY24	Q/Q Change
Revenue	$7.9M	↓ 89.87%
Net Income	$-108.5M	↑ 231.69%
Net Profit Margin	-1.4K%	↓ 1330.9%

	Q2 FY24	Q/Q Change
Revenue	$8.7M	↑ 9.52%
Net Income	$-102.9M	↓ 5.19%
Net Profit Margin	-1.2K%	↑ 184.34%

	Q3 FY24	Q/Q Change
Revenue	$11.9M	↑ 37.17%
Net Income	$-93.6M	↓ 9.04%
Net Profit Margin	-788.06%	↑ 400.45%

	FY18	Y/Y Change
Profit	$90.3M	↓ 142.93%

	FY19	Y/Y Change
Profit	$6.5M	↓ 92.84%

	FY20	Y/Y Change
Profit	$1.1B	↑ 17117.61%

	FY21	Y/Y Change
Profit	$5.8M	↓ 99.48%

	FY22	Y/Y Change
Profit	$6.9M	↑ 19.43%

	FY23	Y/Y Change
Profit	$84.3M	↑ 1126.48%

	Q2 FY23	Q/Q Change
Profit	$2.3M	↓ 25.95%

	Q3 FY23	Q/Q Change
Profit	$1.8M	↓ 20.19%

	Q4 FY23	Q/Q Change
Profit	$77.2M	↑ 4160.19%

	Q1 FY24	Q/Q Change
Profit	$6.6M	↓ 91.4%

	Q2 FY24	Q/Q Change
Profit	$7.2M	↑ 9.26%

	Q3 FY24	Q/Q Change
Profit	$6.6M	↓ 9.02%

	FY18	Y/Y Change
Operating Cash Flow	$-260.7M	↑ 18.88%
Investing Cash Flow	$-512.5M	↓ 3476.56%
Financing Cash Flow	$659.4M	↑ 92.9%

	FY19	Y/Y Change
Operating Cash Flow	$-528.7M	↑ 102.83%
Investing Cash Flow	$-143.2M	↓ 72.06%
Financing Cash Flow	$607.6M	↓ 7.85%

	FY20	Y/Y Change
Operating Cash Flow	$664.3M	↓ 225.64%
Investing Cash Flow	$442.7M	↓ 409.23%
Financing Cash Flow	$426.8M	↓ 29.77%

	FY21	Y/Y Change
Operating Cash Flow	$-378.2M	↓ 156.93%
Investing Cash Flow	$-1.0B	↓ 326.45%
Financing Cash Flow	$13.3M	↓ 96.88%

	FY22	Y/Y Change
Operating Cash Flow	$-460.0M	↑ 21.64%
Investing Cash Flow	$325.4M	↓ 132.46%
Financing Cash Flow	$3.1M	↓ 76.98%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$-131.5M	↓ 14.42%
Investing Cash Flow	$45.6M	↓ 76.6%
Financing Cash Flow	$847.0K	↓ 68.3%

Sage Therapeutics Technicals Summary

Sell

Neutral

Buy

Sage Therapeutics is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Sage Therapeutics Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Sage Therapeutics Inc	15.67%	-51.47%	-74.32%	-86.65%	-92.48%
Regeneron Pharmaceuticals, Inc.	-5.73%	-34.03%	-17.11%	13.66%	87.56%
Biontech Se	4.48%	30.56%	7.36%	-56.46%	225.6%
Alnylam Pharmaceuticals, Inc.	-0.55%	10.11%	28.49%	30.99%	109.19%
Vertex Pharmaceuticals Incorporated	-11.79%	-16.36%	-1.97%	78.33%	80.59%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Sage Therapeutics Inc	NA	NA	0.74	-6.5	-0.49	-0.3	NA	9.02
Regeneron Pharmaceuticals, Inc.	17.51	17.51	1.06	45.07	0.17	0.07	NA	272.04
Biontech Se	160.8	NA	0.04	-3.11	-0.02	-0.01	NA	79.73
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	-0.19	-15.01	-0.03	NA	0.25
Vertex Pharmaceuticals Incorporated	32.84	NA	1.17	0.55	-0.03	0.12	NA	60.65

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Sage Therapeutics Inc	Hold	$305.9M	-92.48%	NA	0.0%
Regeneron Pharmaceuticals, Inc.	Buy	$77.8B	87.56%	17.51	33.61%
Biontech Se	Buy	$26.7B	225.6%	160.8	-15.36%
Alnylam Pharmaceuticals, Inc.	Buy	$30.8B	109.19%	NA	-15.86%
Vertex Pharmaceuticals Incorporated	Buy	$102.1B	80.59%	32.84	-4.51%

About Sage Therapeutics

sage therapeutics is a neuroscience-focused company developing medicines to treat life-threatening, rare cns disorders. our mission is to make life better for patients with central nervous systems diseases by discovering, developing, and delivering important new medicines to the market. to achieve that mission we leverage compelling science, a robust clinical foundation, strong partnerships, and a world-class team of founders, advisors, investors, scientists and managers. sage’s lead program, sage-547, is in clinical development for super-refractory status epilepticus (srse) and is the first of many compounds the company is developing in its portfolio of potential seizure medicines. sage’s robust chemistry platform has generated multiple new compounds that target the gabaa and nmda receptors, which have demonstrated preclinical activity. sage therapeutics is a private company launched in 2010 by an experienced team of r&d leaders, cns experts and investors.

Organization	Sage Therapeutics
Employees	487
CEO	Mr. Barry E. Greene
Industry	Health Technology

Management People of Sage Therapeutics

Name	Title
Mr. Barry E. Greene	President, CEO & Director
Mr. Christopher Benecchi	Chief Operating Officer
Dr. Laura Gault M.D., Ph.D.	Chief Medical Officer
Mr. Mike Quirk Ph.D.	Chief Scientific Officer
Ashley Kaplowitz	Director of Investor Relations
Mr. Gregory Shiferman	Senior VP & General Counsel
Ms. Pamela Herbster	VP & Head of People
Dr. Helen Colquhoun	Senior Vice President of Drug Safety & Pharmacovigilance
Ms. Vanessa Procter	Senior Vice President of Corporate Affairs
Dr. Aaron Koenig M.D.	Medical Director of Early Clinical Development

Important FAQs about investing in Sage Therapeutics from India :

What is Sage Therapeutics share price today?

Sage Therapeutics share price today stands at $5.61, Open: $5.06 ; Previous Close: $5.00 ; High: $5.61 ; Low: $4.96 ; 52 Week High: $28.26 ; 52 Week Low: $4.62. The stock opens at $5.06, after a previous close of $5.00. The stock reached a daily high of $5.61 and a low of $4.96, with a 52-week high of $28.26 and a 52-week low of $4.62.

Can Indians buy Sage Therapeutics shares?

Yes, Indians can invest in the Sage Therapeutics (SAGE) from India.

With INDmoney, you can buy Sage Therapeutics at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Sage Therapeutics at zero transaction cost.

How can I buy Sage Therapeutics shares from India?

It is very easy to buy Sage Therapeutics from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Sage Therapeutics be purchased?

Yes, you can buy fractional shares of Sage Therapeutics with INDmoney app.

What are the documents required to start investing in Sage Therapeutics stocks?

To start investing in Sage Therapeutics, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.